David MoatazediPresident and Chief Executive OfficerDavid Moatazedi has served as our President, Chief Executive Officer and as a member of our board of directors since May 2018. From March 2016 to May 2018, Mr. Moatazedi served as Senior Vice President at Allergan, Inc., and division head of the U.S. Medical Aesthetics division, which includes facial aesthetics, plastic surgery and skin care products. Mr. Moatazedi has worked in various leadership capacities within Allergan since March 2005, including as Vice President, Sales and Marketing of the U.S. Facial Aesthetics division from August 2014 to March 2016 and Vice President, Sales and Market of the U.S. Plastic Surgery division from February 2013 to August 2014. Prior to Allergan, Mr. Moatazedi was a district manager at Novartis Pharmaceuticals for the Dermatology division. Since March 2017, Mr. Moatazedi has also served as a director of Obalon Therapeutics, Inc.. Mr. Moatazedi holds an M.B.A. from Pepperdine University and a B.A. from California State University, Long Beach.
Lauren SilvernailChief Financial Officer and Executive Vice President, Corporate Development
Lauren Silvernail has served as our Chief Financial Officer and Executive Vice President, Corporate Development since May 2018. From December 2015 to May 2018 Mrs. Silvernail served as the Chief Financial Officer and Chief Business Officer of Revance Therapeutics, Inc. From March 2013 to December 2015, Mrs. Silvernail served as the Chief Financial Officer and Executive Vice President, Corporate Development of Revance Therapeutics, Inc.. From 2003 to 2012, Mrs. Silvernail was Chief Financial Officer and Vice President of Corporate Development at ISTA Pharmaceuticals, Inc., a pharmaceutical research and development company. During her tenure at ISTA, revenues grew to more than $160 million and headcount increased to more than 340 employees by the time ISTA was purchased by Bausch & Lomb in June 2012. From 1995 to 2003, Mrs. Silvernail served in various operating and corporate development positions with Allergan, Inc., a pharmaceutical company, including Vice President, Business Development. Prior to joining Allergan, Inc., Mrs. Silvernail worked at Glenwood Ventures, an investment firm, as a General Partner. She currently serves on the board of directors and the audit committee of Nicox S.A. Mrs. Silvernail holds a B.A. in Biophysics from the University of California, Berkeley and an M.B.A. from the Anderson Graduate School of Management at the University of California, Los Angeles.
Rui AvelarChief Medical Officer and Head of Research and DevelopmentRui Avelar, M.D., has served as our Chief Medical Officer, and as the Chief Medical Officer of ALPHAEON, since January 2014. From March 2011 to December 2013, he served as Chief Medical Officer of Allergan Medical, where he was responsible for clinical development, clinical operations, safety, medical writing, biostatistics and regulatory matters. Dr. Avelar holds a M.D. from the University of Toronto and has received training accreditation in Sports Medicine from the Canadian Academy of Sports Medicine.
Michael Mazen JafarChief Marketing Officer
Michael Mazen Jafar joined Evolus as Chief Marketing Officer in June 2018. Mr. Jafar formerly served as Vice President of Marketing, U.S. Medical Aesthetics at Allergan™. Prior to that, Michael led the assessment and integration of Zeltiq along with the upstream development plan for Allergan’s aesthetic portfolio of brands including Botox® Cosmetic, JUVEDERM® Collection, KYBELLA® & Natrelle®.
Mr. Jafar has nearly 15 years of commercial and executive experience building multiple market leading pharmaceutical, device and topical brands in eyecare and medical aesthetics.
Michael is a board member of the Irvine Public School Foundation, an Orange County based philanthropic organization, he holds an MBA from University of Southern California and a B.A. in International finance and Supply Chain from the University of San Diego.